Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#4153 Type 1 gastric neuroendocrine tumors (g-NETs) with vitamin B12 deficiency-caused nerve function damage – A case Report

Introduction: Patients with type 1 g-NETs frequently experience VitB12 deficiency as a result of autoimmune gastritis. VitB12 deficiency infrequently leads to neurological symptoms. Unfortunately, the delay in diagnosing this condition often results in prolonged suffering and increased financial burden for the patients.

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen X, Chen R, Cui L,

Keywords: type 1 gastric neuroendocrine tumor, vitamin B12 deficiency, nerve function damage, case report,

#3560 Nutritional status in patients with neuroendocrine tumors: A single ENETS Centre of Excellence experience

Introduction: Studies show that 14–68% of patients with neuroendocrine tumors (NETS) are at risk of or are malnourished. Patients’ dependent on NET type, primary or treatment are at risk of Vitamin B12, A, D E, iron deficiencies, pancreatic enzyme insufficiency (PEI) and a high HbA1c.

Conference:

Presenting Author:

Authors: Burke D, Almeamar H, O'Toole D, Barnes L, Crowley R,

Keywords: malnutrition, deficiencies, Pancreatic enzyme insufficiency, HbA1c's,